Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 11/2019

01-11-2019 | Positron Emission Tomography | Original Article

Searching for diagnostic properties of novel fluorine-18-labeled d-allose

Authors: Jun Toyohara, Hiroyuki Yamamoto, Tetsuro Tago

Published in: Annals of Nuclear Medicine | Issue 11/2019

Login to get access

Abstract

Objective

Two fluorine-18-labeled analogues, 3-deoxy-3-[18F]fluoro-d-allose (3-[18F]FDA) and 6-deoxy-6-[18F]fluoro-d-allose (6-[18F]FDA), were synthesized and their potentials of diagnostic property were characterized.

Methods

In vitro rat red blood cell (RBC) transport and phosphorylation by yeast hexokinase were evaluated in comparison with 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG). The rate of protein binding in pooled human serum was measured by an ultrafiltration method. In vivo metabolite analysis in mice was also performed. Biodistribution, urine excretion, and in vivo renal kinetics in mice were compared with 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS).

Results

Rat RBC uptake of 3- and 6-[18F]FDA (7.8 ± 2.5%ID and 10.2 ± 4.8%ID, respectively) was significantly lower than that of [18F]FDG (44.7 ± 8.7%ID). RBC uptake of 3-[18F]FDA was inhibited by d-glucose (30%) and cytochalasin B (40%), indicating the involvement of GLUT1-dependent transport. In contrast, 6-[18F]FDA transport was not inhibited by d-glucose and cytochalasin B. 3- and 6-[18F]FDA were not phosphorylated by yeast hexokinase under the conditions that result in 60% conversion of [18F]FDG into [18F]FDG-6-phosphate within 30 min. Serum protein binding of 3- and 6-[18F]FDA was negligible. Metabolic transformation of both tracers was not detected in plasma and urine at 30 min after injection. The highest tissue uptake of both tracers was observed in kidneys. Heart and brain uptake of both tracers was below blood levels throughout the biodistribution studies (until 120 min after injection). No significant uptake in the bone was observed, indicating the absence of de-fluorination in mice. In vivo PET imaging visualized rapid excretion of the administered 3- and 6-[18F]FDA from the kidneys, with minimal tracer accumulation in other organs. The urine excretion rate of 3-[18F]FDA was much lower than that of 6-[18F]FDA and [18F]FDS.

Conclusions

3- and 6-[18F]FDA might be unsatisfactory for tumor imaging. In contrast, these tracers demonstrated high levels of kidney uptake and excretion, low serum protein binding, and high metabolic stability as preferable properties for renal imaging. Notably, the urine excretion rate and kidney uptake kinetics of 6-[18F]FDA were comparable with those of the potential renal imaging agent [18F]FDS. Further validation studies in animal models are required to confirm the feasibility of 6-[18F]FDA as a functional renal imaging agent.
Appendix
Available only for authorised users
Literature
1.
Gao D, Kawai N, Tamiya T. The anti-inflammatory effects of D-allose contribute to attenuation of cerebral ischemia-reperfusion injury. Med Hypothesis. 2011;76:911–3.CrossRef
2.
Gao D, Kawai N, Nakamura T, Lu F, Fei Z, Tamiya T. Anti-inflammatory effect of d-allose in cerebral ischemia/reperfusion injury in rats. Neurol Med Chir (Tokyo). 2013;53:365–74.CrossRef
3.
Shinohara N, Nakamura T, Abe Y, Hifumi T, Kawakita K, Shinomiya A, Tamiya T, Tokuda M, Keep RF, Yamamoto T, Kuroda Y. D-Allose attenuates overexpression of inflammatory cytokines after cerebral ischemia/reperfusion injury in Gerbil. J Stroke Cerebrovasc Dis. 2016;25:2184–8.CrossRefPubMed
4.
Ishihara Y, Katayama K, Sakabe M, Kitamura M, Aizawa M, Takara M, Itoh K. Antioxidant properties of rare sugar d-allose: effects on mitochondrial reactive oxygen species production in Neuro2A cells. J Biosci Bioeng. 2011;112:638–42.CrossRefPubMed
5.
Kashiwagi H, Asano E, Noguchi C, Sui L, Hossain A, Akamoto S, Okano K, Tokuda M, Suzuki Y. Beneficial effect of D-allose isolated islet culture prior to islet transplantation. J Hepatobiliary Pancreat Sci. 2016;23:37–42.CrossRefPubMed
6.
Yamada K, Noguchi C, Kamitori K, Dong Y, Hirata Y, Hossain MA, Tsukamoto I, Tokuda M, Yamaguchi F. Rare sugar D-allose strongly induces thioredoxin-interacting protein and inhibits osteoclast differentiation in Raw264 cells. Nutr Res. 2012;32:116–23.CrossRefPubMed
7.
Kimura S, Zhang GX, Nishiyama A, Nagai Y, Nakagawa T, Miyanaka H, Fujisawa Y, Miyatake A, Nagai T, Tokuda M, Abe Y. D-Allose, an all-cis aldo-hexose, suppresses development of salt-induced hypertension in Dahl rats. J Hypertens. 2005;23:1887–944.CrossRefPubMed
8.
Hirooka K, Miyamoto O, Jinming P, Du Y, Itano T, Baba T, Tokuda M, Shiraga F. Neuroprotective effects of d-allose against retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2006;47:1653–7.CrossRefPubMed
9.
Liu Y, Nakamura T, Toyoshima T, Shinomiya A, Tamiya T, Tokuda M, Keep RF, Itano T. The effects of d-allose on transient ischemic neuronal death and analysis of its mechanism. Brain Res Bull. 2014;109:127–31.CrossRefPubMed
10.
Sui L, Dong Y, Watanabe Y, Yamaguchi F, Hatano N, Izumori K, Tokuda M. Growth inhibitory effect of d-allose on human ovarian carcinoma cells in vitro. Anticancer Res. 2005;25:2639–44.PubMed
11.
Sui L, Dong Y, Wtanabe Y, Yamaguchi F, Hatano N, Tsukamoto I, Izumori K, Tokuda M. The inhibitory effect and possible mechanisms of d-allose on cancer cell proliferation. Int J Oncol. 2005;27:907–12.PubMed
12.
Yamaguchi F, Takata M, Kamitori K, Nonaka M, Dong Y, Sui L, Tokuda M. Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27Kip1. Int J Oncol. 2008;32:377–85.PubMed
13.
Noguchi C, Kamitori K, Hossain A, Hoshikawa H, Katagi A, Dong Y, Sui L, Tokuda M, Yamaguchi F. d-Allose inhibits cancer cell growth by reducing GLUT1 expression. Tohoku J Exp Med. 2016;238:131–41.CrossRefPubMed
14.
Tewson TJ, Welch MJ, Raichle ME. [18F]-Labeled 3-deoxy-3-fluoro-d-glucose: synthesis and preliminary biodistribution data. J Nucl Med. 1978;19:1339–455.PubMed
15.
Neal TR, Schumann WC, Berridge MS, Landau BR. Synthesis of [18F]-6-deoxy-6-fluoro-d-glucose ([18F]6FDG), a potential tracer for glucose transport. J Labelled Comp Radiopharm. 2005;48:845–54.CrossRef
16.
Ashique R, Chirakal RV, Hughes DW, Schrobligen GJ. Two-step regio- and stereoselective syntheses of [19F]- and [18F]-2-deoxy-2-(R)-fluoro-β-d-allose. Carbohydr Res. 2006;341:457–66.CrossRefPubMed
17.
Ashique R, Chirakal R, Schrobilgen GJ, Hughes DW, Farncombe T, Gulenchyn K, Labiris R, Truman T, Saab C. Reactivity and selectivity of F2 toward 3,4,6-tri-O-acetyl-d-glucal in anhydrous HF: synthesis of [18F]2-fluoro-2-deoxy-β-d-allose and its use for the detection of a breast tumor. In: Gakh AA, Kirk KL, editors. ACS Symposium Series (Fluorinated Heterocycles) Vol. 1003, Chapter 10, 2019. pp. 211–235.
18.
Iga Y, Matsuo T. D-allose metabolism in rats. J Jpn Soc Nutr Food Sci 2010;63:17–9 (Japanese)
19.
Wakabayashi H, Werner RA, Hayakawa N, Javadi MS, Xinyu C, Hermann K, Rowe SP, Lapa C, Higuchi T. Initial preclinical evaluation of 18F-fluorodeoxysorbitol PET as a novel functional renal imaging agent. J Nucl Med. 2016;57:1625–8.CrossRefPubMed
20.
Werner RA, Wakabayashi H, Chen X, Hirano M, Shinaji T, Lapa C, Rowe SP, Javadi MS, Higuchi T. Functional renal imaging with 18F-FDS PET in rat models of renal disorders. J Nucl Med. 2018;59:828–32.CrossRefPubMed
21.
Werner RA, Ordonez AA, Sanchez-Bautista J, Marcus C, Lapa C, Rowe SP, Pomper MG, Leal JP, Lodge MA, Javadi MS, Jain SK, Higuchi T. Novel functional renal PET imaging with 18F-FDS in human subjects. Clin Nucl Med. 2019;44:410–1.CrossRefPubMedPubMedCentral
22.
Li ZB, Wu Z, Cao Q, Dick DW, Tseng JR, Gambhir SS, Chen X. The synthesis of 18F-FDS and its potential application in molecular imaging. Mol Imaging Biol. 2008;10:92–8.CrossRefPubMed
23.
Minosako Y, Nemoto M, Ino S, Shirakami Y, Kurami M. Uptake of FDG (2-fluro-2-deoxy-d-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cell. Kaku Igaku 2003;40:23–30 (Japanese)
24.
Van Rijn CJS, Herscheid JDM, Visser GWM, Hoekstra A. On the stereoselectivity of the reaction of [18F]acetylhypofluorite with glucals. Int J Appl Radiat Isot. 1985;36:111–5.CrossRef
25.
Amini N, Nakao R, Schou M, Halldin C. Determination of plasma protein binding of positron emission tomography radioligands by high-performance frontal analysis. J Pharm Biomed Anal. 2014;98:140–3.CrossRefPubMed
26.
Ishii K, Kikuchi Y, Matsuyama S, Kanai Y, Kotani K, Ito T, Yamazaki H, Funaki Y, Iwata R, Itoh M, Yanai K, Hatazawa J, Itoh N, Tanizaki D, Amano D, Yamada M, Yamaguchi T. First achievement of less than 1 mm FWHM resolution in practical semiconductor animal PET scanner. Nucl Instrum Meth A. 2007;576:435–40.CrossRef
27.
Loten EG, Regen DM, Park CR. Transport of D-allose by isolated fat-cells: an effect of adenosine trisphosphate on insulin stimulated transport. J Cell Physiol. 1976;89:651–60.CrossRefPubMed
28.
29.
30.
31.
32.
Lipowska M, Jarkas N, Voll RJ, Nye JA, Klenc J, Goodman MM, Taylor AT. Re(CO)3([18F]FEDA), a novel 18F PET renal tracer: radiosynthesis and preclinical evaluation. Nucl Med Biol. 2018;58:42–50.CrossRefPubMed
33.
Awasthi V, Pathuri G, Agashe HB, Gali H. Synthesis and in vivo evaluation of p-18F-fluorohippurate as a new radiopharmaceutical for assessment of renal function by PET. J Nucl Med. 2011;522:147–53.CrossRef
Metadata
Title
Searching for diagnostic properties of novel fluorine-18-labeled d-allose
Authors
Jun Toyohara
Hiroyuki Yamamoto
Tetsuro Tago
Publication date
01-11-2019
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 11/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-019-01398-x

Other articles of this Issue 11/2019

Annals of Nuclear Medicine 11/2019 Go to the issue

Original Article

Effect of drugs containing glucose on FDG-PET image quality

Special Article

Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials

Original Article

Clinical utility of the normal database of 123I-iodoamphetamine brain perfusion single photon emission computed tomography for statistical analysis using computed tomography-based attenuation correction: a multicenter study

Original Article

A pitfall of white matter reference regions used in [18F] florbetapir PET: a consideration of kinetics

Original Article

In vivo preclinical PET/CT imaging of carbon-11-labeled aminoglycerol probe for the diagnosis of liver fibrosis

Original Article

18F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading